• Mashup Score: 0

    The U.S. Supreme Court unanimously ruled in favor of Regeneron and Sanofi that two of Amgen’s patents for PCSK9 inhibitor technology were invalid, allowing alirocumab to stay on the U.S. market. As Healio previously reported, in 2016 a U.S. District Court jury in Delaware decided that two patents related to monoclonal antibodies for PCSK9 inhibition held by Amgen, which makes

    Tweet Tweets with this article
    • ICYMI: The U.S. Supreme Court unanimously ruled in favor of #Regeneron and Sanofi that two of #Amgen’s patents for #PCSK9inhibitor technology were invalid, allowing #alirocumab to stay on the U.S. market @endocrinetoday #cardiotwitter https://t.co/jfNhzt4gN2

  • Mashup Score: 0

    The U.S. Supreme Court unanimously ruled in favor of Regeneron and Sanofi that two of Amgen’s patents for PCSK9 inhibitor technology were invalid, allowing alirocumab to stay on the U.S. market. As Healio previously reported, in 2016 a U.S. District Court jury in Delaware decided that two patents related to monoclonal antibodies for PCSK9 inhibition held by Amgen, which makes

    Tweet Tweets with this article
    • ICYMI: The U.S. Supreme Court unanimously ruled in favor of #Regeneron and Sanofi that two of #Amgen’s patents for #PCSK9inhibitor technology were invalid, allowing #alirocumab to stay on the U.S. market @endocrinetoday #cardiotwitter https://t.co/jfNhzt4gN2

  • Mashup Score: 0

    The U.S. Supreme Court unanimously ruled in favor of Regeneron and Sanofi that two of Amgen’s patents for PCSK9 inhibitor technology were invalid, allowing alirocumab to stay on the U.S. market. As Healio previously reported, in 2016 a U.S. District Court jury in Delaware decided that two patents related to monoclonal antibodies for PCSK9 inhibition held by Amgen, which makes

    Tweet Tweets with this article
    • The U.S. Supreme Court unanimously ruled in favor of #Regeneron and Sanofi that two of #Amgen’s patents for #PCSK9inhibitor technology were invalid, allowing #alirocumab to stay on the U.S. market @endocrinetoday #cardiotwitter https://t.co/jfNhzt4gN2